Sa1020 Hepatitis B Virus Infection and Risk of Non-Hodgkin Lymphoma: A Meta-Analysis of Case-Control Studies

Kanth, Rajan; Inaganti, Anupama; Samji, Naga Swetha; Komanapalli, Sarah D.; Borg, Brian B.; Roy, Praveen K.

doi:10.1016/s0016-5085(13)63618-5

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lamivudine was initially available to prevent HBV reactivation clinically and serologically. Later, several meta-analyses (Dong et al, 2013;Kanth et al, 2013;Kohrt et al, 2006;Li et al, 2014;Loomba et al, 2008;Martyak et al, 2008) assessed the overall benefits of prophylactic lamivudine therapy in chemotherapy-induced HBV reactivation. A few studies (Dai et al, 2004;Lee et al, 2012;Lim et al, 2002;Lin et al, 2014;Yan et al, 2012;Yeo et al, 2004aYeo et al, , 2005Yun et al, 2011) favoured the prophylactic lamivudine for patients with chemotherapy-induced HBV reactivation.…”

Section: Discussionmentioning

confidence: 99%

“…However, one prospective RCT (Long et al, 2011) suggested the incidence of hepatitis, chemotherapy disruptions and overall death between the prophylactic lamivudine group and non-prophylaxis group were not statistically different. Later, several meta-analyses (Dong et al, 2013;Kanth et al, 2013;Kohrt et al, 2006;Li et al, 2014;Loomba et al, 2008;Martyak et al, 2008) assessed the overall benefits of prophylactic lamivudine therapy in chemotherapy-induced HBV reactivation. However, these articles either focused on haematological tumours or mixed solid and haematological malignancy together.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis

Dai

Arshad

et al. 2017

Eur J Cancer Care

View full text Add to dashboard Cite

Hepatitis B virus (HBV) reactivation is a remarkable risk during the chemotherapy for solid tumour patients. Nucleos(t)ide analogues (NAs) are recommended as prophylaxis for the reactivation of HBV infection in some cancer patients prior to systemic chemotherapy. Therefore, we performed a meta-analysis aiming to determine the efficacy of prophylactic lamivudine on prevention of HBV reactivation and its related negative outcomes among solid tumour patients with chronic HBV infection receiving systemic chemotherapy. The primary outcome was HBV reactivation, and the secondary outcomes were HBV-related hepatitis, chemotherapy disruption, mortality and tyrosine-methio-nine-aspartate-aspartate (YMDD) mutations. Twelve original researches involving 1,101 patients were analysed in this study. The relative risk of HBV reactivation in patients with lamivudine prophylaxis was significantly lower than that without prophylaxis (RR = 0.17, 95% CL: 0.10-0.29, p < .00001). Lamivudine prophylaxis reduced the relative risk of hepatitis (p < .00001), chemotherapy disruptions (p = .01) and mortality (p = .08) due to HBV reactivation. Lamivudine prophylaxis is effective in reducing HBV reactivation and its related negative outcomes, such as hepatitis and chemotherapy disruption and mortality among chemotherapeutic solid tumour patients with chronic HBV infection. Future studies should lay more emphasis on the early HBV screening, mode of treatment and duration of NAs prophylaxis among solid tumour patients receiving chemotherapy.

show abstract